In vitro and in vivo metabolism of psilocybin's active metabolite psilocin.
Autor: | Thomann J; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Kolaczynska KE; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Stoeckmann OV; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Rudin D; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Vizeli P; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Hoener MC; Neuroscience Research, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Pryce CR; Department of Psychiatry, Psychotherapy and Psychosomatics, Preclinical Laboratory for Translational Research Into Affective Disorders, University of Zurich, Zurich, Switzerland., Vollenweider FX; Department of Psychiatry, Psychotherapy and Psychosomatics, Neurophenomenology and Consciousness, University of Zurich, Zurich, Switzerland., Liechti ME; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Duthaler U; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.; Institute of Forensic Medicine, Department of Biomedical Engineering, University of Basel, Basel, Switzerland.; Institute of Forensic Medicine, Health Department Basel-Stadt, Basel, Switzerland. |
---|---|
Jazyk: | angličtina |
Zdroj: | Frontiers in pharmacology [Front Pharmacol] 2024 Apr 29; Vol. 15, pp. 1391689. Date of Electronic Publication: 2024 Apr 29 (Print Publication: 2024). |
DOI: | 10.3389/fphar.2024.1391689 |
Abstrakt: | In vivo , psilocybin is rapidly dephosphorylated to psilocin which induces psychedelic effects by interacting with the 5-HT Competing Interests: FXV is currently on the board of directors of the Heffter Research Institute and a scientific advisor for the MIND Foundation. MCH is an employee of F. Hoffmann-La Roche. MEL is a consultant for Mind Medicine Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Thomann, Kolaczynska, Stoeckmann, Rudin, Vizeli, Hoener, Pryce, Vollenweider, Liechti and Duthaler.) |
Databáze: | MEDLINE |
Externí odkaz: |